-
Something wrong with this record ?
Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials
M. Haluzík, ME. Al-Sofiani, AYY. Cheng, F. Lauand, L. Melas-Melt, J. Rosenstock
Language English Country England, Great Britain
Document type Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial
Grant support
Sanofi
PubMed
39245809
DOI
10.1111/dom.15811
Knihovny.cz E-resources
- MeSH
- Glucagon-Like Peptide-1 Receptor Agonists MeSH
- Diabetes Mellitus, Type 2 * drug therapy blood MeSH
- Adult MeSH
- Drug Combinations MeSH
- Glycated Hemoglobin analysis metabolism drug effects MeSH
- Hypoglycemic Agents * therapeutic use MeSH
- Insulin Glargine * therapeutic use MeSH
- Blood Glucose * drug effects metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Peptides * therapeutic use administration & dosage MeSH
- Randomized Controlled Trials as Topic MeSH
- Glucagon-Like Peptide-2 Receptor MeSH
- Blood Glucose Self-Monitoring MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Randomized Controlled Trial MeSH
AIM: To evaluate the efficacy of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) using derived time-in-range (dTIR). METHODS: Participant-level data from LixiLan-L, LixiLan-O and LixiLan-G were pooled and dTIR (70-180 mg/dL), derived time-above-range (> 180 mg/dL) and derived time-below-range (dTBR; < 70 mg/dL) were calculated from participant seven-point self-monitored blood glucose profiles. RESULTS: This pooled analysis included data from 2420 participants receiving iGlarLixi (n = 1093), iGlar (n = 836), Lixi (n = 234) or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) (n = 257). Numerically greater improvements in least square (LS) means dTIR were seen from baseline to end of treatment (EOT) with iGlarLixi (25.7%) versus iGlar (15.8%), Lixi (11.7%) or GLP-1 RA (16.2%). At EOT, the mean (standard deviation) dTBR was 0.71% ± 3.4%, 0.61% ± 3.2%, 0.08% ± 1.0% and 0.0% ± 0.0% for iGlarLixi, iGlar, Lixi and GLP-1 RA, respectively. In a subgroup analysis, participants aged younger than 65 years (n = 1690) and 65 years or older (n = 713) showed numerically greater improvements in LS means dTIR from baseline to EOT with iGlarLixi versus iGlar, Lixi or GLP-1 RA. CONCLUSIONS: iGlarLixi achieved improvements in dTIR, with low dTBR values, providing further evidence to inform clinical outcomes with the use of iGlarLixi.
Department of Internal Medicine King Saud University Riyadh Saudi Arabia
Department of Medicine University of Toronto Toronto Canada
Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic
Division of Endocrinology Diabetes and Metabolism Johns Hopkins University Baltimore Maryland USA
IVIDATA Life Sciences Levallois Perret France
Velocity Clinical Research at Medical City Dallas Dallas Texas USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003667
- 003
- CZ-PrNML
- 005
- 20250206104609.0
- 007
- ta
- 008
- 250121s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/dom.15811 $2 doi
- 035 __
- $a (PubMed)39245809
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Haluzík, Martin $u Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $1 https://orcid.org/0000000202016888 $7 xx0000707
- 245 10
- $a Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials / $c M. Haluzík, ME. Al-Sofiani, AYY. Cheng, F. Lauand, L. Melas-Melt, J. Rosenstock
- 520 9_
- $a AIM: To evaluate the efficacy of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) using derived time-in-range (dTIR). METHODS: Participant-level data from LixiLan-L, LixiLan-O and LixiLan-G were pooled and dTIR (70-180 mg/dL), derived time-above-range (> 180 mg/dL) and derived time-below-range (dTBR; < 70 mg/dL) were calculated from participant seven-point self-monitored blood glucose profiles. RESULTS: This pooled analysis included data from 2420 participants receiving iGlarLixi (n = 1093), iGlar (n = 836), Lixi (n = 234) or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) (n = 257). Numerically greater improvements in least square (LS) means dTIR were seen from baseline to end of treatment (EOT) with iGlarLixi (25.7%) versus iGlar (15.8%), Lixi (11.7%) or GLP-1 RA (16.2%). At EOT, the mean (standard deviation) dTBR was 0.71% ± 3.4%, 0.61% ± 3.2%, 0.08% ± 1.0% and 0.0% ± 0.0% for iGlarLixi, iGlar, Lixi and GLP-1 RA, respectively. In a subgroup analysis, participants aged younger than 65 years (n = 1690) and 65 years or older (n = 713) showed numerically greater improvements in LS means dTIR from baseline to EOT with iGlarLixi versus iGlar, Lixi or GLP-1 RA. CONCLUSIONS: iGlarLixi achieved improvements in dTIR, with low dTBR values, providing further evidence to inform clinical outcomes with the use of iGlarLixi.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a diabetes mellitus 2. typu $x farmakoterapie $x krev $7 D003924
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a inzulin glargin $x terapeutické užití $7 D000069036
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a hypoglykemika $x terapeutické užití $7 D007004
- 650 12
- $a krevní glukóza $x účinky léků $x metabolismus $7 D001786
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a peptidy $x terapeutické užití $x aplikace a dávkování $7 D010455
- 650 _2
- $a selfmonitoring glykemie $7 D015190
- 650 _2
- $a glykovaný hemoglobin $x analýza $x metabolismus $x účinky léků $7 D006442
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a receptor pro glukagonu podobný peptid 2 $7 D000067758
- 650 _2
- $a agonisté receptoru pro glukagonu podobný peptid 1 $7 D000097789
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Al-Sofiani, Mohammed E $u Department of Internal Medicine, King Saud University, Riyadh, Saudi Arabia $u Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, Maryland, USA $1 https://orcid.org/0000000344209378
- 700 1_
- $a Cheng, Alice Y Y $u Department of Medicine, University of Toronto, Toronto, Canada
- 700 1_
- $a Lauand, Felipe $u Sanofi, Paris, France
- 700 1_
- $a Melas-Melt, Lydie $u IVIDATA Life Sciences, Levallois-Perret, France
- 700 1_
- $a Rosenstock, Julio $u Velocity Clinical Research at Medical City Dallas, Dallas, Texas, USA $1 https://orcid.org/0000000183243275 $7 nlk20050164876
- 773 0_
- $w MED00005425 $t Diabetes, obesity and metabolism $x 1463-1326 $g Roč. 26, č. 11 (2024), s. 5046-5055
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39245809 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104605 $b ABA008
- 999 __
- $a ok $b bmc $g 2263429 $s 1239674
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 26 $c 11 $d 5046-5055 $e 20240908 $i 1463-1326 $m Diabetes, obesity and metabolism $n Diabetes Obes Metab $x MED00005425
- GRA __
- $p Sanofi
- LZP __
- $a Pubmed-20250121
